Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Jan 17, 2020

SELL
$20.93 - $35.1 $418,600 - $702,000
-20,000 Closed
0 $0
Q3 2019

Oct 03, 2024

BUY
$22.08 - $47.08 $441,599 - $941,600
20,000 New
20,000 $573,000
Q2 2019

Oct 03, 2024

BUY
$22.67 - $35.0 $453,400 - $700,000
20,000 New
20,000 $556,000
Q1 2019

Oct 03, 2024

BUY
$26.93 - $34.7 $538,600 - $694,000
20,000 New
20,000 $664,000
Q4 2018

Oct 03, 2024

BUY
$27.23 - $45.56 $544,600 - $911,200
20,000 New
20,000 $581,000
Q3 2018

Oct 04, 2024

BUY
$37.57 - $50.34 $751,400 - $1.01 Million
20,000 New
20,000 $920,000
Q2 2018

Oct 04, 2024

BUY
$27.75 - $40.17 $555,000 - $803,400
20,000 New
20,000 $747,000
Q4 2017

Oct 04, 2024

BUY
$28.45 - $37.14 $569,000 - $742,800
20,000 New
20,000 $687,000
Q2 2017

Aug 09, 2017

BUY
N/A
20,000
20,000 $517,000

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.31B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Commerzbank Aktiengesellschaft Portfolio

Follow Commerzbank Aktiengesellschaft and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commerzbank Aktiengesellschaft , based on Form 13F filings with the SEC.

News

Stay updated on Commerzbank Aktiengesellschaft with notifications on news.